Viralytics Limtied (ASX:VLA) has received final approval for phase 1 clinical trials of Cavatak from UK regulators for patients with bladder cancer.
The biotech company says the phase 1 trial is a two part open label study designed to evaluate the safety and tolerability of CAVATAK administered alone as well as with chemotherapy.
The trial will be undertaken at the University of Surrey as part of its ongoing collaboration with Viralytics.
Cavatak is a proprietary formulation of a common cold virus that has been shown to preferentially infect and attack cancer cells.
Viralytics reported a net loss of $5.5 million in the 2014 financial year.
